“Strong underlying demand for our products and the start of our European Union launch of Defitelio led to significant revenue growth in the second quarter,” says Bruce C. Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc. “We have successfully completed three transactions in 2014, including our recently announced acquisition of the rights to defibrotide in the Americas. With an expanding clinical development pipeline targeted in the sleep and hematology/oncology therapeutic areas and our continued focus on business development, we believe that we are poised to provide significant financial growth in 2014 and beyond.”

Adjusted net income attributable to Jazz Pharmaceuticals plc for the second quarter of 2014 was $127.8 million, compared to $88.3 million, for the second quarter of 2013.

Total revenues for the second quarter of 2014 were $291.2 million, an increase of 40% over total revenues of $208.3 million for the second quarter of 2013. This increase was driven primarily by net product sales of narcolepsy treatment Xyrem (sodium oxybate) oral solution, Erwinaze/Erwinase (asparaginase Erwinia chrysanthemi), and defibrotide, marketed under the name Defitelio (defibrotide) in Europe. Total revenues include net product sales, royalties, and contract revenues.

Net product sales for the second quarter of 2014 were as follows:

  • Xyrem net sales increased by 43% to $191.4 million in the second quarter of 2014 compared to $133.7 million in the second quarter of 2013. During the second quarter of 2014, the average number of active Xyrem patients increased to 11,750.
  • Erwinaze/Erwinase net sales increased by 7% to $47.9 million in the second quarter of 2014 compared to $44.9 million in the second quarter of 2013.
  • Defitelio/defibrotide net sales in the second quarter of 2014 were $20.2 million compared to pro forma net sales of $10.1 million in the second quarter of 2013. Jazz Pharmaceuticals plc acquired indirect majority control of Gentium S.p.A. (Gentium) on January 23, 2014. The pro forma information represents net sales of Defitelio/defibrotide as if the acquisition of Gentium had closed on January 1, 2013.
  • Net sales of Prialt were $5.8 million in the second quarter of 2014, an increase of 24% compared to $4.7 million in the second quarter of 2013.
  • Net sales of the company’s psychiatry products were $11.7 million in the second quarter of 2014 compared to $11.8 million in the second quarter of 2013.
  • Net sales of other products in the second quarter of 2014 were $12.1 million compared to $11.5 million in the second quarter of 2013. On a pro forma basis, net sales of other products for the second quarter of 2013 were $13.9 million, which included net sales of active pharmaceutical ingredients by Gentium as if the Gentium acquisition had closed on January 1, 2013.